Starpharma (ASX:SPL) share price surges higher on COVID product update

The Starpharma Holdings Limited (ASX:SPL) share price is surging higher on Thursday after releasing an update on its Viraleze product…
The post Starpharma (ASX:SPL) share price surges higher on COVID product update appeared first on The Motley Fool Australia. –

A woman kicks a giant COVID-19 molecule, indicating positive share price movement for biotech companies

The Starpharma Holdings Limited (ASX: SPL) share price has been a strong performer on Thursday.

At the time of writing, the dendrimer products developer’s shares are up 6% to $1.89.

Why is the Starpharma share price racing higher?

Investors have been buying Starpharma’s shares following the release of an update on its Viraleze antiviral nasal spray.

According to the release, the Viraleze antiviral nasal spray is now available for purchase by consumers in Europe via the company’s webstore.

This follows the recent launch of Viraleze in the United Kingdom through LloydsPharmacy’s 1,400 stores and online business. It is also expected to be available via independent United Kingdom pharmacies later this month.

What is Viraleze?

Viraleze is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013). This is virucidal, irreversibly inactivating >99.9% of coronavirus/SARS-CoV-2 within one minute.

These antiviral studies were conducted at the renowned Scripps Research Institute in the United States and a number of other specialist virology laboratories.

It isn’t just multiple strains of COVID-19 that Viraleze has been demonstrated to have potent antiviral activity. It also has been found to have potent antiviral activity against RSV (respiratory syncytial virus), MERS, and SARS.

Management notes that the antiviral active in Viraleze works by irreversibly blocking coronavirus SARS-CoV-2 ‘spike’ proteins from binding to human airway cells. This forms a physical barrier to respiratory viruses in the nasal cavity and has multiple unique advantages. One of these is its ability to inactivate the virus either before or after exposure.

Starpharma’s CEO, Dr Jackie Fairley, commented: “We are delighted to be rolling out Viraleze in Europe following the UK launch. The product has been very well received in the UK, and we hope that Viraleze will provide European consumers with added peace of mind.”

“In addition to making Viraleze available direct to consumers in Europe via, commercial discussions for distribution continue in parallel. Starpharma is actively engaged in discussions with a variety of organisations in the region, including sporting teams, which have expressed interest in Viraleze,” she concluded.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Starpharma (ASX:SPL) share price surges higher on COVID product update appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!